The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine model

Naoki Yoshioka(Ogaki Municipal Hospital), Takayoshi Suganami(Nagoya Industrial Science Research Institute), Miyako Tanaka(Nagoya Industrial Science Research Institute), Akiko Watanabe(Duke University), Kenji Ono(Nagoya City University), Ayaka Ito(Nagoya University Hospital), Kozue Ochi(Nagoya University), Mitsuhiro Fujishiro(Bunkyo University), Masatoshi Ishigami(Nagoya University), Yoshihiro Ogawa(Kyushu University), Yukihiro Shiraki(Nagoya University), Michiko Itoh(Tokyo Medical and Dental University), Atsushi Enomoto(Nagoya University), Makoto Sawada(Fujita Health University), Tomoo Ogi(Nagasaki University)
Biomedicine & Pharmacotherapy
May 21, 2021
Cited by 29


Related Papers